See the DrugPatentWatch profile for halcinonide
What does “Sun Pharma halcinonide solution” refer to in the patent context?
“Halcinonide” is a topical corticosteroid used for skin inflammation. A “Halcinonide solution” product made or marketed by Sun Pharma is typically covered by a mix of IP layers: formulation/patent protections for the specific product form, patents on manufacturing processes, and sometimes regulatory exclusivities that affect when generic products can launch.
Which patents could cover a halcinonide solution by Sun Pharma?
A patent search for “Sun Pharma halcinonide solution” usually comes down to identifying claims in these categories:
- Formulation patents tied to a specific drug-in-solution composition (for example, excipients, concentration ranges, or stability-related design).
- Manufacturing or process patents (how the solution is made, purified, sterilized/preserved, or packaged).
- Packaging or delivery-device patents (less common for a plain solution, but possible).
- Use-related patents (approved indication claims or specific treatment regimens), depending on the jurisdiction and claim language.
Without a specific patent number, country, or product dossier, the exact patents and their claim scope can’t be determined from the product name alone.
Is Sun Pharma’s halcinonide solution protected by patents right now? How do you check?
To check whether Sun Pharma’s halcinonide solution is still protected, you normally match:
- The country/regulator (for example, US FDA, UK MHRA, India CDSCO, EU EMA).
- The exact product label (strength, dosage form, and composition).
- The referenced application (originator vs generic/marketing authorisation holder).
- Patent/publication data linked to that marketing authorization (if available in the relevant database).
Common places to check (by jurisdiction) include patent registers and regulator-linked “patent list” systems used for medicines. The key is that patents are jurisdiction-specific and often not tied cleanly to just the drug name.
When would patents or exclusivity for halcinonide solution expire?
Patent expiry depends on:
- Filing date and any patent term adjustments in the country.
- Whether patents are primary (composition/process) or secondary (improvements).
- Patent term extensions (where applicable) and whether patents are granted vs only published.
- Litigation or settlements that can delay market entry even after a first expiry.
If you share the country (or the specific patent number/publication), it’s possible to estimate the likely expiry window from that record.
Are there generic or “halcinonide solution” products that could launch if patents expire?
Generic entry generally depends on:
- Whether a generic can file without infringing active patents.
- Whether it can rely on data exclusivity periods or other regulatory exclusivities.
- Whether any “skin” topical corticosteroid-specific patents still block the exact formulation or process claims.
Even if a composition patent expires, a later-granted formulation or process patent can keep a product protected.
What side of the IP story should you look for: Sun Pharma vs competitors?
Depending on your goal (freedom-to-operate vs investing vs due diligence), the most useful search is usually:
- Sun Pharma’s own patent families covering halcinonide topical solutions.
- Any competitor patent filings that claim alternate formulations or processes.
- Court records or opposition/invalidity filings that can change enforceability.
What I need from you to give a specific patent answer
If you want a concrete response (exact patent numbers, assignees, claims, and likely expiry), send at least one of:
- The country (e.g., India, US, EU, UK).
- The product strength (e.g., percentage) and full brand name as sold.
- A patent number or publication number.
- A link to the product page or patent listing you’re looking at.
Sources are limited here because the request doesn’t include any patent publication details or jurisdiction.